Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.

Autor: Elgamal, Ola A.1 (AUTHOR), Mehmood, Abeera1 (AUTHOR), Jeon, Jae Yoon2 (AUTHOR), Carmichael, Bridget1 (AUTHOR), Lehman, Amy3 (AUTHOR), Orwick, Shelley J.1 (AUTHOR), Truxall, Jean1 (AUTHOR), Goettl, Virginia M.1 (AUTHOR), Wasmuth, Ronni1 (AUTHOR), Tran, Minh1 (AUTHOR), Mitchell, Shaneice1 (AUTHOR), Lapalombella, Rosa1 (AUTHOR), Eathiraj, Sudharshan4 (AUTHOR), Schwartz, Brian4 (AUTHOR), Stegmaier, Kimberly5 (AUTHOR), Baker, Sharyn D.1,2 (AUTHOR), Hertlein, Erin1 (AUTHOR) erin.hertlein@osumc.edu, Byrd, John C.1,2 (AUTHOR) john.byrd@osumc.edu
Zdroj: Journal of Hematology & Oncology. 1/28/2020, Vol. 13 Issue 1, p1-14. 14p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje